Compare Boston Scientific Corporation (BSX) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Progressive Corp — how do they compare? Boston Scientific Corporation trades at $43.22 (market cap $66.37B), while Progressive Corp trades at $208.29 (market cap $131.91B). The key difference: Progressive Corp is the larger of the two by market cap, and Progressive Corp pays a 6.13% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | PGR | |
|---|---|---|
Market Cap | $66.37B | $131.91B |
Sector | Health | Financials |
52-Week High | $108.14 | $252.68 |
52-Week Low | $42.63 | $190.40 |
Enterprise Value | $75.94B | $140.14B |
Dividend Yield | — | 6.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Progressive (PGR) trades at $234.48, up 1.63% today, near its consensus price target of $240.89. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and a net income margin of 12.93%. Technical indicators are bullish, with the price above key moving averages. Recent news highlights focus on Q2 2026 earnings expectations due July 15, 2026.
Outlook is positive given earnings growth and analyst buy ratings, but risks include potential earnings misses and competitive pressures. The stock offers value with a P/E of 11.93, below industry averages, supporting a bullish view for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
